These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21904858)

  • 1. Utility of the Etest GRD for detecting Staphylococcus aureus with reduced susceptibility to glycopeptides in cystic fibrosis patients.
    Filleron A; Chiron R; Reverdy ME; Jean-Pierre H; Dumitrescu O; Aleyrangues L; Counil F; Jumas-Bilak E; Marchandin H
    Eur J Clin Microbiol Infect Dis; 2012 Apr; 31(4):599-604. PubMed ID: 21904858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
    Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
    J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).
    Voss A; Mouton JW; van Elzakker EP; Hendrix RG; Goessens W; Kluytmans JA; Krabbe PF; de Neeling HJ; Sloos JH; Oztoprak N; Howe RA; Walsh TR
    Ann Clin Microbiol Antimicrob; 2007 Sep; 6():9. PubMed ID: 17892555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM; Rossney AS; O'Connell B
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.
    Wootton M; MacGowan AP; Walsh TR; Howe RA
    J Clin Microbiol; 2007 Feb; 45(2):329-32. PubMed ID: 17108069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK.
    Kirby A; Graham R; Williams NJ; Wootton M; Broughton CM; Alanazi M; Anson J; Neal TJ; Parry CM
    J Antimicrob Chemother; 2010 Apr; 65(4):721-4. PubMed ID: 20124288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effectiveness of common hospital hand disinfectants against methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, and heterogeneous glycopeptide-intermediate S. aureus.
    Wootton M; Walsh TR; Davies EM; Howe RA
    Infect Control Hosp Epidemiol; 2009 Mar; 30(3):226-32. PubMed ID: 19199533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.
    Wootton M; Bennett PM; MacGowan AP; Walsh TR
    J Antimicrob Chemother; 2005 Nov; 56(5):944-7. PubMed ID: 16157619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Leonard SN; Rossi KL; Newton KL; Rybak MJ
    J Antimicrob Chemother; 2009 Mar; 63(3):489-92. PubMed ID: 19136530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy].
    Lecaillon E; Gueudet P; Wooton M; Walsh TR; Macgowan AP; Jones ME
    Pathol Biol (Paris); 2002 Nov; 50(9):525-9. PubMed ID: 12490414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus.
    Amiali NM; Mulvey MR; Berger-Bächi B; Sedman J; Simor AE; Ismail AA
    J Antimicrob Chemother; 2008 Jan; 61(1):95-102. PubMed ID: 17962217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus and how to test it.
    Hawkey PM
    Clin Microbiol Infect; 2009 Dec; 15 Suppl 7():2-9. PubMed ID: 19951328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.
    Rong SL; Leonard SN
    Ann Pharmacother; 2010 May; 44(5):844-50. PubMed ID: 20332341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
    Cartolano GL; Cheron M; Benabid D; Leneveu M; Boisivon A;
    Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands.
    Van Griethuysen A; Van 't Veen A; Buiting A; Walsh T; Kluytmans J
    J Clin Microbiol; 2003 Jun; 41(6):2487-91. PubMed ID: 12791870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
    Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
    J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
    Richter SS; Satola SW; Crispell EK; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Diekema DJ; Doern GV
    J Clin Microbiol; 2011 Dec; 49(12):4203-7. PubMed ID: 21976769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
    Riederer K; Shemes S; Chase P; Musta A; Mar A; Khatib R
    J Clin Microbiol; 2011 Jun; 49(6):2147-50. PubMed ID: 21490190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.